CA2387359A1 - Immunological assay for detection of antibodies in celiac disease - Google Patents
Immunological assay for detection of antibodies in celiac disease Download PDFInfo
- Publication number
- CA2387359A1 CA2387359A1 CA002387359A CA2387359A CA2387359A1 CA 2387359 A1 CA2387359 A1 CA 2387359A1 CA 002387359 A CA002387359 A CA 002387359A CA 2387359 A CA2387359 A CA 2387359A CA 2387359 A1 CA2387359 A1 CA 2387359A1
- Authority
- CA
- Canada
- Prior art keywords
- substrate
- gliadin
- antibodies
- transglutaminase
- ttg
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 208000015943 Coeliac disease Diseases 0.000 title claims abstract description 33
- 238000001514 detection method Methods 0.000 title claims abstract description 20
- 238000010324 immunological assay Methods 0.000 title description 3
- 239000000758 substrate Substances 0.000 claims abstract description 61
- 238000000034 method Methods 0.000 claims abstract description 37
- 108060008539 Transglutaminase Proteins 0.000 claims abstract description 13
- 102000003601 transglutaminase Human genes 0.000 claims abstract description 13
- 108010061711 Gliadin Proteins 0.000 claims description 36
- 108010050792 glutenin Proteins 0.000 claims description 27
- 239000011159 matrix material Substances 0.000 claims description 14
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 14
- 239000007787 solid Substances 0.000 claims description 14
- 230000035945 sensitivity Effects 0.000 claims description 13
- 102000007327 Protamines Human genes 0.000 claims description 12
- 108010007568 Protamines Proteins 0.000 claims description 12
- 229950008679 protamine sulfate Drugs 0.000 claims description 11
- 238000003745 diagnosis Methods 0.000 claims description 10
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 10
- 102000002260 Alkaline Phosphatase Human genes 0.000 claims description 8
- 108020004774 Alkaline Phosphatase Proteins 0.000 claims description 8
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 claims description 8
- 229920001184 polypeptide Polymers 0.000 claims description 7
- 239000000463 material Substances 0.000 claims description 5
- 108010001336 Horseradish Peroxidase Proteins 0.000 claims description 3
- 108010046334 Urease Proteins 0.000 claims description 2
- 230000027455 binding Effects 0.000 claims description 2
- 239000012634 fragment Substances 0.000 claims description 2
- 230000000890 antigenic effect Effects 0.000 claims 1
- 230000003100 immobilizing effect Effects 0.000 claims 1
- 210000002966 serum Anatomy 0.000 abstract description 8
- 102100038095 Protein-glutamine gamma-glutamyltransferase 2 Human genes 0.000 description 69
- 108700039882 Protein Glutamine gamma Glutamyltransferase 2 Proteins 0.000 description 68
- HZWWPUTXBJEENE-UHFFFAOYSA-N 5-amino-2-[[1-[5-amino-2-[[1-[2-amino-3-(4-hydroxyphenyl)propanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoic acid Chemical compound C1CCC(C(=O)NC(CCC(N)=O)C(=O)N2C(CCC2)C(=O)NC(CCC(N)=O)C(O)=O)N1C(=O)C(N)CC1=CC=C(O)C=C1 HZWWPUTXBJEENE-UHFFFAOYSA-N 0.000 description 9
- 239000000427 antigen Substances 0.000 description 9
- 102000036639 antigens Human genes 0.000 description 9
- 108091007433 antigens Proteins 0.000 description 9
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 8
- 238000003556 assay Methods 0.000 description 7
- 239000006225 natural substrate Substances 0.000 description 7
- 239000011248 coating agent Substances 0.000 description 6
- 238000000576 coating method Methods 0.000 description 6
- 230000000903 blocking effect Effects 0.000 description 5
- 239000011534 wash buffer Substances 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000000968 intestinal effect Effects 0.000 description 4
- 101710087459 Gamma-gliadin Proteins 0.000 description 3
- 241000209140 Triticum Species 0.000 description 3
- 235000021307 Triticum Nutrition 0.000 description 3
- 229960000583 acetic acid Drugs 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 238000001574 biopsy Methods 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 238000003018 immunoassay Methods 0.000 description 3
- 238000010166 immunofluorescence Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 229920000155 polyglutamine Polymers 0.000 description 3
- 108010040003 polyglutamine Proteins 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- OFNXOACBUMGOPC-HZYVHMACSA-N 5'-hydroxystreptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](CO)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O OFNXOACBUMGOPC-HZYVHMACSA-N 0.000 description 2
- 108010068370 Glutens Proteins 0.000 description 2
- 241000282414 Homo sapiens Species 0.000 description 2
- 108010081750 Reticulin Proteins 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 235000004554 glutamine Nutrition 0.000 description 2
- 235000021312 gluten Nutrition 0.000 description 2
- OFNXOACBUMGOPC-UHFFFAOYSA-N hydroxystreptomycin Natural products CNC1C(O)C(O)C(CO)OC1OC1C(C=O)(O)C(CO)OC1OC1C(N=C(N)N)C(O)C(N=C(N)N)C(O)C1O OFNXOACBUMGOPC-UHFFFAOYSA-N 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- OKPOKMCPHKVCPP-UHFFFAOYSA-N isoorientaline Natural products C1=C(O)C(OC)=CC(CC2C3=CC(OC)=C(O)C=C3CCN2C)=C1 OKPOKMCPHKVCPP-UHFFFAOYSA-N 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- JTQHYPFKHZLTSH-UHFFFAOYSA-N reticulin Natural products COC1CC(OC2C(CO)OC(OC3C(O)CC(OC4C(C)OC(CC4OC)OC5CCC6(C)C7CCC8(C)C(CCC8(O)C7CC=C6C5)C(C)O)OC3C)C(O)C2OC)OC(C)C1O JTQHYPFKHZLTSH-UHFFFAOYSA-N 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- LBCZOTMMGHGTPH-UHFFFAOYSA-N 2-[2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethoxy]ethanol Chemical compound CC(C)(C)CC(C)(C)C1=CC=C(OCCOCCO)C=C1 LBCZOTMMGHGTPH-UHFFFAOYSA-N 0.000 description 1
- HSTOKWSFWGCZMH-UHFFFAOYSA-N 3,3'-diaminobenzidine Chemical compound C1=C(N)C(N)=CC=C1C1=CC=C(N)C(N)=C1 HSTOKWSFWGCZMH-UHFFFAOYSA-N 0.000 description 1
- XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 1
- 244000075850 Avena orientalis Species 0.000 description 1
- 235000007319 Avena orientalis Nutrition 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 240000005979 Hordeum vulgare Species 0.000 description 1
- 235000007340 Hordeum vulgare Nutrition 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010025476 Malabsorption Diseases 0.000 description 1
- 208000004155 Malabsorption Syndromes Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 241000209056 Secale Species 0.000 description 1
- 235000007238 Secale cereale Nutrition 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000006472 autoimmune response Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- -1 but not limited to Proteins 0.000 description 1
- LLSDKQJKOVVTOJ-UHFFFAOYSA-L calcium chloride dihydrate Chemical compound O.O.[Cl-].[Cl-].[Ca+2] LLSDKQJKOVVTOJ-UHFFFAOYSA-L 0.000 description 1
- 229940052299 calcium chloride dihydrate Drugs 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- KAKKHKRHCKCAGH-UHFFFAOYSA-L disodium;(4-nitrophenyl) phosphate;hexahydrate Chemical compound O.O.O.O.O.O.[Na+].[Na+].[O-][N+](=O)C1=CC=C(OP([O-])([O-])=O)C=C1 KAKKHKRHCKCAGH-UHFFFAOYSA-L 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 235000006171 gluten free diet Nutrition 0.000 description 1
- 235000020884 gluten-free diet Nutrition 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 229940048914 protamine Drugs 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/91—Transferases (2.)
- G01N2333/91045—Acyltransferases (2.3)
- G01N2333/91074—Aminoacyltransferases (general) (2.3.2)
- G01N2333/9108—Aminoacyltransferases (general) (2.3.2) with definite EC number (2.3.2.-)
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Wood Science & Technology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The present invention discloses a method for the detection of antibodies in celiac disease. The method comprises detecting antibodies in serum, to a combination of transglutaminase and a substrate therefor.
Description
IMMZTNOLOGICAL ASSAY FOR DETECTION OF ANTIBODIES IN
CELIAC DISEASE
This application claims the priority of U.S.
provisional application 60/160,548 filed on October 20, 1999, the disclosure of which is incorporated herein by reference.
BACKGROUND OF THE INVENTION
Field of the Invention The present invention relates generally to the field of celiac disease. More particularly, the present invention provides a sensitive immunological assay for the detection of antibodies implicated in celiac disease.
Description of Related Art Celiac disease (CD) is a disease of the intestinal mucosa and is usually manifested in infants and children. CD is associated with an inflammation of the mucosa, which causes malabsorption. Individuals with celiac disease do not tolerate a protein called gluten, which is present in wheat, rye, barley and possibly oats. When exposed to gluten, the immune system of an individual with CD responds by attacking the lining of the small intestine. The only treatment of CD is a gluten-free diet, which usually results in morphological and clinical improvement.
Currently, the routine procedure to detect celiac disease is intestinal biopsy for checking damage to the intestinal lining. Recently, it has been reported that antibodies directed against gliadin, endomysial antigen (EMA), or reticulin can be detected in CD. Thus, ELISAs for gliadin and immunofluorescence assays for EMA and reticulin have been suggested for the diagnosis of CD.
Further, since transglutaminase (tTG) has been identified as the endomysial antigen involved in CD, immunological assays are being proposed to detect
CELIAC DISEASE
This application claims the priority of U.S.
provisional application 60/160,548 filed on October 20, 1999, the disclosure of which is incorporated herein by reference.
BACKGROUND OF THE INVENTION
Field of the Invention The present invention relates generally to the field of celiac disease. More particularly, the present invention provides a sensitive immunological assay for the detection of antibodies implicated in celiac disease.
Description of Related Art Celiac disease (CD) is a disease of the intestinal mucosa and is usually manifested in infants and children. CD is associated with an inflammation of the mucosa, which causes malabsorption. Individuals with celiac disease do not tolerate a protein called gluten, which is present in wheat, rye, barley and possibly oats. When exposed to gluten, the immune system of an individual with CD responds by attacking the lining of the small intestine. The only treatment of CD is a gluten-free diet, which usually results in morphological and clinical improvement.
Currently, the routine procedure to detect celiac disease is intestinal biopsy for checking damage to the intestinal lining. Recently, it has been reported that antibodies directed against gliadin, endomysial antigen (EMA), or reticulin can be detected in CD. Thus, ELISAs for gliadin and immunofluorescence assays for EMA and reticulin have been suggested for the diagnosis of CD.
Further, since transglutaminase (tTG) has been identified as the endomysial antigen involved in CD, immunological assays are being proposed to detect
- 2 -antibodies using tTG as the antigen (Schuppan et al., WO
98/03892, 1998).
Gliadins are a class of proteins that can be isolated from wheat. These include the alpha, gamma, epsilon, delta and omega gliadins. Antibodies to gliadins have been reported in CD. Thus, immunoreactivity is observed against the gliadins as well as against glutenin, which is a partially purified fraction of wheat and contains gliadins.
Transglutaminases (EC 2.3.2.13) are a diverse family of Ca2+ dependent enzymes that are highly ubiquitous and highly conserved across species.
Transglutaminases catalyze the covalent cross-linking of specific proteins through the formation of isopeptide bonds between a-carboxyl groups of glutamine residues in one polypeptide and E-NHz groups of lysine residues in another. The resulting polymer network is stable and resistant or proteolysis, increasing the resistance of tissue to chemical, enzymatic and mechanical disruption.
Of all the transglutaminases, tissue transglutaminases (tTG) is the most widely distributed. tTG provides the focus of the autoimmune response in CD, and has therefore been used for diagnosis of CD.
Although immunoassay techniques have been described for gladins and tTG for the diagnosis of CD, these assays do not detect all cases of celiac disease or sprue that are detected by intestinal biopsy. As a result, there is an ongoing need for the development of sensitive non-invasive tests for the diagnosis of celiac disease.
SUMMARY OF THE INVENTION
The present invention discloses a method for the diagnosis of celiac disease that is more sensitive that the methods of the prior art. The present method comprises detecting antibodies in the sera of patients to a combination of transglutaminase and its substrate
98/03892, 1998).
Gliadins are a class of proteins that can be isolated from wheat. These include the alpha, gamma, epsilon, delta and omega gliadins. Antibodies to gliadins have been reported in CD. Thus, immunoreactivity is observed against the gliadins as well as against glutenin, which is a partially purified fraction of wheat and contains gliadins.
Transglutaminases (EC 2.3.2.13) are a diverse family of Ca2+ dependent enzymes that are highly ubiquitous and highly conserved across species.
Transglutaminases catalyze the covalent cross-linking of specific proteins through the formation of isopeptide bonds between a-carboxyl groups of glutamine residues in one polypeptide and E-NHz groups of lysine residues in another. The resulting polymer network is stable and resistant or proteolysis, increasing the resistance of tissue to chemical, enzymatic and mechanical disruption.
Of all the transglutaminases, tissue transglutaminases (tTG) is the most widely distributed. tTG provides the focus of the autoimmune response in CD, and has therefore been used for diagnosis of CD.
Although immunoassay techniques have been described for gladins and tTG for the diagnosis of CD, these assays do not detect all cases of celiac disease or sprue that are detected by intestinal biopsy. As a result, there is an ongoing need for the development of sensitive non-invasive tests for the diagnosis of celiac disease.
SUMMARY OF THE INVENTION
The present invention discloses a method for the diagnosis of celiac disease that is more sensitive that the methods of the prior art. The present method comprises detecting antibodies in the sera of patients to a combination of transglutaminase and its substrate
- 3 -such as gliadin, glutenin or other peptides having multiple glutamines. The sensitivity of the method detecting antibodies to a combination of tTG and its substrates is greater than the additive sensitivity of detecting antibodies to tTG alone or its substrates alone.
Accordingly, it is an object of the present invention to provide a sensitive method for the diagnosis of celiac disease.
It is another object of the present invention to provide a method of diagnosing celiac disease comprising the step of detecting the presence of antibodies to the combination of tTG and one or more substrates of tTG.
DESCRIPTION OF PREFERRED EMBODIMENTS
The term "substrate of tTG" or "tTG substrate" as used herein for the purposes of specification and claims means a peptide or polypeptide, irrespective of whether or not it is an enzymatic substrate of tTG, that interacts with tTG such that hidden epitopes on the substrate or tTG are exposed, the exposure of the hidden epitopes being detected as a synergistic increase in the detection of antibodies. An example of a substrate of tTg is a peptide or polypeptide having multiple glutamines such as polyglutamine, protamine sulfate or natural substrates such as gliadins and glutenin.
The present invention relates to increasing the sensitivity of diagnosis of celiac disease by detecting the presence of antibodies to tTG in the presence of its substrate. It was unexpectedly observed that when tTG
was allowed to interact with a substrate prior to contact with the sample containing antibodies, the sensitivity of detection increased synergistically.
In one embodiment, the substrate of tTG was gliadin. That the increased sensitivity was not simply due to the detection of antibodies to tTG and to gliadin was demonstrated by the synergistic increase in the
Accordingly, it is an object of the present invention to provide a sensitive method for the diagnosis of celiac disease.
It is another object of the present invention to provide a method of diagnosing celiac disease comprising the step of detecting the presence of antibodies to the combination of tTG and one or more substrates of tTG.
DESCRIPTION OF PREFERRED EMBODIMENTS
The term "substrate of tTG" or "tTG substrate" as used herein for the purposes of specification and claims means a peptide or polypeptide, irrespective of whether or not it is an enzymatic substrate of tTG, that interacts with tTG such that hidden epitopes on the substrate or tTG are exposed, the exposure of the hidden epitopes being detected as a synergistic increase in the detection of antibodies. An example of a substrate of tTg is a peptide or polypeptide having multiple glutamines such as polyglutamine, protamine sulfate or natural substrates such as gliadins and glutenin.
The present invention relates to increasing the sensitivity of diagnosis of celiac disease by detecting the presence of antibodies to tTG in the presence of its substrate. It was unexpectedly observed that when tTG
was allowed to interact with a substrate prior to contact with the sample containing antibodies, the sensitivity of detection increased synergistically.
In one embodiment, the substrate of tTG was gliadin. That the increased sensitivity was not simply due to the detection of antibodies to tTG and to gliadin was demonstrated by the synergistic increase in the
- 4 -detection. Thus, more samples were detected as positive when tTG was allowed to react with its substrate (gliadin) prior to contact with the antibodies, than when either tTG alone or gliadin alone was used as the antigen. Further, when tTG was incubated with a substrate not known to be a natural substrate, i.e., protamine sulfate, a similar increase in sensitivity was observed. Although not intending to be bound by any particular theory, it is considered that tTG undergoes conformational change upon interacting with a substrate and in doing so, exposes epitopes that are relevant in vivo and that are not available without the substrate.
For the method of the present invention, the substrate of tTG is coated on to a solid matrix. Any standard immunoassay solid matrix such as a microtitre plate, beads and the like can be used. Transglutaminase (tTG) can be purified from any source such as murine, porcine, equine, human, monkey etc., or can be prepared by recombinant technology. tTG is also available commercially. Substrates for tTG are, or contain, peptides or polypeptides having multiple glutamine residues. Suitable substrates for tTG may be natural substrates such as gliadins or glutenin, or substrates not known to be natural substrates like protamine sulfate or polyglutamine. When the substrates of tTG
is soluble only in an acidic medium, as is the case with gliadins and glutenin, it is preferable to coat a solid matrix first with the substrate in an acidic medium such as acetic acid. After a suitable period of coating, excess acid is washed away and then tTG is added. In the case of substrates that do not require an acidic medium for solubilization, such as protamine sulfate, substrate and tTg may be coated on a solid matrix in any order or the two may be incubated together in aqueous solution and then coated on to a solid matrix.
For example, in one embodiment, the solid matrix can be coated with gliadin, glutenin or both. In a
For the method of the present invention, the substrate of tTG is coated on to a solid matrix. Any standard immunoassay solid matrix such as a microtitre plate, beads and the like can be used. Transglutaminase (tTG) can be purified from any source such as murine, porcine, equine, human, monkey etc., or can be prepared by recombinant technology. tTG is also available commercially. Substrates for tTG are, or contain, peptides or polypeptides having multiple glutamine residues. Suitable substrates for tTG may be natural substrates such as gliadins or glutenin, or substrates not known to be natural substrates like protamine sulfate or polyglutamine. When the substrates of tTG
is soluble only in an acidic medium, as is the case with gliadins and glutenin, it is preferable to coat a solid matrix first with the substrate in an acidic medium such as acetic acid. After a suitable period of coating, excess acid is washed away and then tTG is added. In the case of substrates that do not require an acidic medium for solubilization, such as protamine sulfate, substrate and tTg may be coated on a solid matrix in any order or the two may be incubated together in aqueous solution and then coated on to a solid matrix.
For example, in one embodiment, the solid matrix can be coated with gliadin, glutenin or both. In a
- 5 -preferred embodiment, the gliadin is gamma gliadin.
Determination of appropriate concentrations of the substrate and tTG are well within the purview of one skilled in the art. In one embodiment, gliadin and glutenin were used in the range of 250ng/ml to 3~,g/ml.
Next, the solid matrix can be coated with tTG. In one embodiment, the concentration of tTG for coating was 5ug/ml to 20ug/ml. After removal of unbound antigens, nonspecific binding sites on the solid matrix can be blocked by methods well known in the art. The tTG plus substrate coated solid matrix can be used immediately for testing patient sera, or can be stored up to 2 years.
Antibodies associated with celiac diseases can be detected in patient sera using the solid matrix as coated above. Briefly, serum at a suitable dilution is incubated with the solid matrix coated with tTG and its substrate. Unbound materials are removed using standard techniques and bound antibodies are detected and quantitated using enzyme linked or fluorescent detection agents. These techniques are well known in the art of immunoassays. For example, for detection of antibodies of human origin, an anti-human IgG, IgM or IgA or antigen binding fragments thereof having a detectable label may be used. The detectable label may be an enzyme including, but not limited to, alkaline phosphatase, ~i-lactamase, ~-galactosidase, urease or horseradish peroxidase. In a preferred embodiment, the label is alkaline phosphatase or horseradish peroxidase.
Suitable substrates for these enzymes are well known in the art and include p-nitrophenyl-phosphate, 5-bromo-4-chloro-3-indolyl-phospate, 3,3-diaminobenzidine, and -phenylenediamine.
The presence of antibodies to tTG plus its substrate is considered to be an indication of the presence of CD.
Determination of appropriate concentrations of the substrate and tTG are well within the purview of one skilled in the art. In one embodiment, gliadin and glutenin were used in the range of 250ng/ml to 3~,g/ml.
Next, the solid matrix can be coated with tTG. In one embodiment, the concentration of tTG for coating was 5ug/ml to 20ug/ml. After removal of unbound antigens, nonspecific binding sites on the solid matrix can be blocked by methods well known in the art. The tTG plus substrate coated solid matrix can be used immediately for testing patient sera, or can be stored up to 2 years.
Antibodies associated with celiac diseases can be detected in patient sera using the solid matrix as coated above. Briefly, serum at a suitable dilution is incubated with the solid matrix coated with tTG and its substrate. Unbound materials are removed using standard techniques and bound antibodies are detected and quantitated using enzyme linked or fluorescent detection agents. These techniques are well known in the art of immunoassays. For example, for detection of antibodies of human origin, an anti-human IgG, IgM or IgA or antigen binding fragments thereof having a detectable label may be used. The detectable label may be an enzyme including, but not limited to, alkaline phosphatase, ~i-lactamase, ~-galactosidase, urease or horseradish peroxidase. In a preferred embodiment, the label is alkaline phosphatase or horseradish peroxidase.
Suitable substrates for these enzymes are well known in the art and include p-nitrophenyl-phosphate, 5-bromo-4-chloro-3-indolyl-phospate, 3,3-diaminobenzidine, and -phenylenediamine.
The presence of antibodies to tTG plus its substrate is considered to be an indication of the presence of CD.
- 6 -The following examples are provided to illustrate the invention and are not intended to be restrictive.
Example 1 This embodiment illustrates the coating of a solid matrix with the antigens (tTG plus substrates) and detection of specific antibodies using the antigen-coated solid matrix. In this illustration, prior to coating the plates with tTG, the microtitre plates are coated with glutenin and gliadin (Y-gliadin). Both glutenin and gliadin were dissolved in 1 mM acetic acid (57 ~.1 glacial acetic acid in 1 L distilled water). at 2.5~.g/ml concentration and mixed to make a uniform solution. One hundred microliters of the glutenin-gamma gliadin mixture were added to each of the microtitre well. Plates were incubated at 2-8°C overnight. Next, the plates were coated with 100~C1 of tTG solution, prepared at a concentration of 10~.g/ml in a coating buffer (7.88 g of Tris-HC1, 8.78 of NaCl, and 0.7358 of calcium chloride dihydrate in 1 L H20). The plates were incubated overnight at 2-8°C, washed four times with tTG
wash buffer (7.888 of Tris-HC1, 8.768 of NaCl, 3.728 of EDTA disodium salt, 1 mM Tween 20 in 1 L Hz0). The washed plates were incubated with blocking buffer (lo calf serum in PBS, 0.090 sodium azide). After blocking, the plates were washed with tTG wash buffer and dried.
Patient serum was diluted 1:50 in serum diluent (1% calf serum in PBS) and 100 u1 of the diluted patient serum was added to the plates and the plates were incubated for 1 hour at room temperature (RT). Unbound materials were removed by washing with PBS. Alkaline phosphatase conjugated anti-human IgA was added to the plates for about 30 minutes. Unbound materials were removed by washing. An alkaline phosphatase substrate was added to develop color, and detection and quantitation was performed using a spectrophotometer.
_ 7 _ The results of an experiment, wherein detection of antibodies was carried out with plates coated with i) tTG, glutenin and gliadin, ii) only glutenin and gliadin, and iii) only tTG are presented below in Table Table 1 Sera ID tTG, gliadin glutenin tTG EMA
and glutenin and gliadin coated titre coated coated (EU/ml) (EU/ml) (EU/ml) Col. A Col. B Col. C Col. D Col. E
98-5901 198.8* 21.0* 33.4* 640*
97-2043 28.7* 5.4 9.7 160*
97-4684 64.8* 6.5 8.0 320*
97-2873 63.4* 6.5 25.4* 160*
97-6405 49.0* 16.2* 0.0 160*
97-2449 35.4* 2.2 0.0 320*
98-1537 68.8* 7.8 19.8 160*
The cutoff value for each assay is 20EU/ml. Values that are above the cutoff value are positive and are indicated by an asterisk. Column A indicates the sera identity. Column E indicates that the sera selected for this analysis are all anti-endomysial antigen positive (Gold Standard diagnostic criteria) as determined by immunofluorescence assay. Column B shows the result of the values obtained by using the method of the present invention. As described above, this method includes pre-coating of the plates with glutenin and gamma gliadin followed by the addition of tTG. In contrast, when the same samples were tested using plates coated with tTG alone (column D) or with glutenin and gamma gliadin, without tTG (column C), most of the values were below the cutoff value and hence would be deemed g _ negative. While not intending to be bound by any particular theory, it is considered that the conditions of column B, allows the tTG to interact with its substrate, gliadin and glutenin, thereby eliciting the Celiac Disease specific epitopes on tTG that can be efficiently recognized by the method of the present invention.
Example 2 This embodiment demonstrates that increased sensitivity is achieved by using a single substrate of tTG. To illustrate this embodiment, the detection was carried out essentially as described in Example 1 for samples that were positive using a combination of glutenin and Y-gliadin. Briefly, microtitre plates were coated with a-gliadin, y-gliadin or glutenin. After washing to remove unbound materials, the plates were incubated with tTG. After incubation, plates were washed and an aliquot of test samples was added to the wells. Color development was carried out by alkaline phosphatase labeled anti-human IgA followed by the addition of a substrate for alkaline phosphatase. Color was quantitated in a spectrophotometer. Samples with a reading of 3 Standard deviations above the control were marked as positive. The results from a representative sample are presented in Table 2.
_ g _ Table 2 Sample a-gliadin y-gliadin glutenin y-gliadin +
glutenin 98-6317 positive positive positive positive 98-3810 positive positive ND positive 98-840 positive positive positive positive 98-6316 positive positive positive positive 98-5798 ND positive positive positive 97-2101 positive positive positive positive 97-6719 positive positive positive positive 97-49 positive ND ND positive 97-1048 positive positive positive positive 1~ inaicates not aeterminea.
These results demonstrate that using a single substrate such as a- or y-gliadin or the partially purified fraction glutenin, which contains gliadins, is equally effective for the method of the present invention.
Example 3 This embodiment demonstrates that to increase sensitivity of the assay, tTG can be incubated with a natural substrate as described above or a substrate not known to be a natural substrate but which contains multiple glutamine residues such as protamine sulfate.
or polyglutamine. To illustrate this embodiment, tTG
was incubated with protamine sulfate essentially as described in Example 1. Briefly, microtiter plates were coated with 50ug/ml solution of protamine sulfate for 2 hours at room temperature. Plates were washed with PBS
and incubated with lug/well tTG for 1 hour at room temperature. Plates were washed with tTG wash buffer, blocked with O.lo Triton-x-100 in PBS, washed three times with tTG wash buffer. Serum samples from patients that were known to be positive from EMA titers were then added to the wells. After incubation for 1 hour at room temperature, plates were washed and alkaline phophatase conjugated anti-human IgA was added. Following incubation for 30 minutes are room temperature, the plates were washed and the substrate for alkaline phosphatase was added. Color was quantitated in a spectrophotometer. The results are presented in Table 3.
Table 3 SAMPLE tTG + protamine tTG + glutenin +
sulfate Y-gliadin 00-3638 positive positive 98-1002 positive positive 98-5901 positive positive 97-2873 positive positive 97-1062 positive positive 97-6405 positive positive 97-3082 positive positive These results indicate that all samples that were positive using tTG plus glutenin and gliadin, were also found to be positive with tTG plus protamine sulfate.
Thus, both natural substrates of tTG and other peptides or polypeptides containing multiple glutamine residues can be used for the method of the present invention.
In a variation of this illustration, plates were coated with protamine sulfate, and then blocked with blocking buffer containing 0.1o triton x-100 in PBS
prior to being coated with tTG and the plates were washed with tTG wash buffer. Detection was carried out as above. No difference was observed between blocking first and then incubating with tTG and incubating with tTG and then blocking.
These data indicate that the increased sensitivity observed in the present invention is achieved by allowing tTG to interact with its natural or unnatural substrates. While not intending to be bound by any particular theory, it is considered that tTG interacting with its substrate more accurately represents the situation in vivo and therefore, the sensitivity of the assay is closer to the sensitivity of the immunofluorescence detection techniques for the presence of EMA immunoreactivity in intestinal biopsied sections.
Increasing the sensitivity of detection will help in the diagnosis of celiac disease without the necessity of a biopsy.
From the foregoing, it will be obvious to those skilled in the art that various modifications in the above-described methods, and compositions can be made without departing from the spirit and scope of the invention. Accordingly, the invention may be embodied in other specific forms without departing from the spirit or essential characteristics thereof. Present examples and embodiments, therefore, are to be considered in all respects as illustrative and not restrictive, and all changes which come within the meaning and range of equivalency of the specifications are therefore intended to be embraced therein.
Example 1 This embodiment illustrates the coating of a solid matrix with the antigens (tTG plus substrates) and detection of specific antibodies using the antigen-coated solid matrix. In this illustration, prior to coating the plates with tTG, the microtitre plates are coated with glutenin and gliadin (Y-gliadin). Both glutenin and gliadin were dissolved in 1 mM acetic acid (57 ~.1 glacial acetic acid in 1 L distilled water). at 2.5~.g/ml concentration and mixed to make a uniform solution. One hundred microliters of the glutenin-gamma gliadin mixture were added to each of the microtitre well. Plates were incubated at 2-8°C overnight. Next, the plates were coated with 100~C1 of tTG solution, prepared at a concentration of 10~.g/ml in a coating buffer (7.88 g of Tris-HC1, 8.78 of NaCl, and 0.7358 of calcium chloride dihydrate in 1 L H20). The plates were incubated overnight at 2-8°C, washed four times with tTG
wash buffer (7.888 of Tris-HC1, 8.768 of NaCl, 3.728 of EDTA disodium salt, 1 mM Tween 20 in 1 L Hz0). The washed plates were incubated with blocking buffer (lo calf serum in PBS, 0.090 sodium azide). After blocking, the plates were washed with tTG wash buffer and dried.
Patient serum was diluted 1:50 in serum diluent (1% calf serum in PBS) and 100 u1 of the diluted patient serum was added to the plates and the plates were incubated for 1 hour at room temperature (RT). Unbound materials were removed by washing with PBS. Alkaline phosphatase conjugated anti-human IgA was added to the plates for about 30 minutes. Unbound materials were removed by washing. An alkaline phosphatase substrate was added to develop color, and detection and quantitation was performed using a spectrophotometer.
_ 7 _ The results of an experiment, wherein detection of antibodies was carried out with plates coated with i) tTG, glutenin and gliadin, ii) only glutenin and gliadin, and iii) only tTG are presented below in Table Table 1 Sera ID tTG, gliadin glutenin tTG EMA
and glutenin and gliadin coated titre coated coated (EU/ml) (EU/ml) (EU/ml) Col. A Col. B Col. C Col. D Col. E
98-5901 198.8* 21.0* 33.4* 640*
97-2043 28.7* 5.4 9.7 160*
97-4684 64.8* 6.5 8.0 320*
97-2873 63.4* 6.5 25.4* 160*
97-6405 49.0* 16.2* 0.0 160*
97-2449 35.4* 2.2 0.0 320*
98-1537 68.8* 7.8 19.8 160*
The cutoff value for each assay is 20EU/ml. Values that are above the cutoff value are positive and are indicated by an asterisk. Column A indicates the sera identity. Column E indicates that the sera selected for this analysis are all anti-endomysial antigen positive (Gold Standard diagnostic criteria) as determined by immunofluorescence assay. Column B shows the result of the values obtained by using the method of the present invention. As described above, this method includes pre-coating of the plates with glutenin and gamma gliadin followed by the addition of tTG. In contrast, when the same samples were tested using plates coated with tTG alone (column D) or with glutenin and gamma gliadin, without tTG (column C), most of the values were below the cutoff value and hence would be deemed g _ negative. While not intending to be bound by any particular theory, it is considered that the conditions of column B, allows the tTG to interact with its substrate, gliadin and glutenin, thereby eliciting the Celiac Disease specific epitopes on tTG that can be efficiently recognized by the method of the present invention.
Example 2 This embodiment demonstrates that increased sensitivity is achieved by using a single substrate of tTG. To illustrate this embodiment, the detection was carried out essentially as described in Example 1 for samples that were positive using a combination of glutenin and Y-gliadin. Briefly, microtitre plates were coated with a-gliadin, y-gliadin or glutenin. After washing to remove unbound materials, the plates were incubated with tTG. After incubation, plates were washed and an aliquot of test samples was added to the wells. Color development was carried out by alkaline phosphatase labeled anti-human IgA followed by the addition of a substrate for alkaline phosphatase. Color was quantitated in a spectrophotometer. Samples with a reading of 3 Standard deviations above the control were marked as positive. The results from a representative sample are presented in Table 2.
_ g _ Table 2 Sample a-gliadin y-gliadin glutenin y-gliadin +
glutenin 98-6317 positive positive positive positive 98-3810 positive positive ND positive 98-840 positive positive positive positive 98-6316 positive positive positive positive 98-5798 ND positive positive positive 97-2101 positive positive positive positive 97-6719 positive positive positive positive 97-49 positive ND ND positive 97-1048 positive positive positive positive 1~ inaicates not aeterminea.
These results demonstrate that using a single substrate such as a- or y-gliadin or the partially purified fraction glutenin, which contains gliadins, is equally effective for the method of the present invention.
Example 3 This embodiment demonstrates that to increase sensitivity of the assay, tTG can be incubated with a natural substrate as described above or a substrate not known to be a natural substrate but which contains multiple glutamine residues such as protamine sulfate.
or polyglutamine. To illustrate this embodiment, tTG
was incubated with protamine sulfate essentially as described in Example 1. Briefly, microtiter plates were coated with 50ug/ml solution of protamine sulfate for 2 hours at room temperature. Plates were washed with PBS
and incubated with lug/well tTG for 1 hour at room temperature. Plates were washed with tTG wash buffer, blocked with O.lo Triton-x-100 in PBS, washed three times with tTG wash buffer. Serum samples from patients that were known to be positive from EMA titers were then added to the wells. After incubation for 1 hour at room temperature, plates were washed and alkaline phophatase conjugated anti-human IgA was added. Following incubation for 30 minutes are room temperature, the plates were washed and the substrate for alkaline phosphatase was added. Color was quantitated in a spectrophotometer. The results are presented in Table 3.
Table 3 SAMPLE tTG + protamine tTG + glutenin +
sulfate Y-gliadin 00-3638 positive positive 98-1002 positive positive 98-5901 positive positive 97-2873 positive positive 97-1062 positive positive 97-6405 positive positive 97-3082 positive positive These results indicate that all samples that were positive using tTG plus glutenin and gliadin, were also found to be positive with tTG plus protamine sulfate.
Thus, both natural substrates of tTG and other peptides or polypeptides containing multiple glutamine residues can be used for the method of the present invention.
In a variation of this illustration, plates were coated with protamine sulfate, and then blocked with blocking buffer containing 0.1o triton x-100 in PBS
prior to being coated with tTG and the plates were washed with tTG wash buffer. Detection was carried out as above. No difference was observed between blocking first and then incubating with tTG and incubating with tTG and then blocking.
These data indicate that the increased sensitivity observed in the present invention is achieved by allowing tTG to interact with its natural or unnatural substrates. While not intending to be bound by any particular theory, it is considered that tTG interacting with its substrate more accurately represents the situation in vivo and therefore, the sensitivity of the assay is closer to the sensitivity of the immunofluorescence detection techniques for the presence of EMA immunoreactivity in intestinal biopsied sections.
Increasing the sensitivity of detection will help in the diagnosis of celiac disease without the necessity of a biopsy.
From the foregoing, it will be obvious to those skilled in the art that various modifications in the above-described methods, and compositions can be made without departing from the spirit and scope of the invention. Accordingly, the invention may be embodied in other specific forms without departing from the spirit or essential characteristics thereof. Present examples and embodiments, therefore, are to be considered in all respects as illustrative and not restrictive, and all changes which come within the meaning and range of equivalency of the specifications are therefore intended to be embraced therein.
Claims (18)
1. A method for diagnosis of celiac disease in an individual comprising the steps of:
(a) contacting transglutaminase with a substrate therefor; and (b) detecting the presence of antibodies to the combination of transglutaminase and the substrate from (a), wherein the presence of the antibodies to the combination is indicative of celiac disease and wherein the sensitivity of diagnosis of celiac disease is higher with detection of antibodies to the combination of transglutaminase and the substrate than with detection of antibodies to transglutaminase or the substrate alone.
(a) contacting transglutaminase with a substrate therefor; and (b) detecting the presence of antibodies to the combination of transglutaminase and the substrate from (a), wherein the presence of the antibodies to the combination is indicative of celiac disease and wherein the sensitivity of diagnosis of celiac disease is higher with detection of antibodies to the combination of transglutaminase and the substrate than with detection of antibodies to transglutaminase or the substrate alone.
2. The method of claim 1, wherein the substrate is a peptide or polypeptide having multiple glutamine residues.
3. The method of claim 1, wherein the substrate is gliadin.
4. The method of claim 1, wherein the substrate is glutenin.
5. The method of claim l, wherein the substrate is gliadin and glutenin.
6. The method of claim 2, wherein the substrate is protamine sulfate.
7. The method of claim 3, wherein the gliadin is selected from the group consisting of .alpha.-gliadin and .gamma.-gliadin.
8. The method of claim 5, wherein the gliadin is .gamma.-gliadin.
9. A method for the detection of antibodies to a combination of transglutaminase and a substrate thereof in a sample comprising the steps of a) immobilizing a substrate of tTG on a solid matrix;
b) incubating transglutaminase with the immobilized substrate to form immobilized transglutaminase-substrate complexes;
c) contacting the sample with the immobilized transglutaminase-substrate complexes to form immobilized antibody-(transglutaminase-substrate) complexes;
d) contacting immobilized antibody-(transglutaminase-substrate) complexes with a labeled affinity molecule to form labeled immobilized antibody-(transglutaminase-substrate) complexes, wherein the labeled affinity molecule has a specific affinity for the antibodies;
e) removing unimmobilized labeled materials; and f) estimating the amount of antibodies in the sample from the amount of label immobilized.
b) incubating transglutaminase with the immobilized substrate to form immobilized transglutaminase-substrate complexes;
c) contacting the sample with the immobilized transglutaminase-substrate complexes to form immobilized antibody-(transglutaminase-substrate) complexes;
d) contacting immobilized antibody-(transglutaminase-substrate) complexes with a labeled affinity molecule to form labeled immobilized antibody-(transglutaminase-substrate) complexes, wherein the labeled affinity molecule has a specific affinity for the antibodies;
e) removing unimmobilized labeled materials; and f) estimating the amount of antibodies in the sample from the amount of label immobilized.
10. The method of claim 9, wherein the substrate is a peptide or polypeptide having multiple glutamine residues.
11. The method of claim 9, wherein the substrate is gliadin.
12. The method of claim 9, wherein the substrate is glutenin.
13. The method of claim 9, wherein the substrate is gliadin and glutenin.
14. The method of claim 10, wherein the substrate is protamine sulfate.
15. The method of claim 11, wherein the gliadin is selected from the group consisting of .alpha.-gliadin and .gamma.-gliadin.
16. The method of claim 13, wherein the gliadin is .gamma.-gliadin.
17. The method of claim 9, wherein the labeled affinity molecule is selected from the group consisting of anti-human IgG, IgA, IgM and antigenic binding fragments thereof.
18. The method of claim 17 wherein the label on the affinity molecule is selected from the group consisting of alkaline phosphatase, horseradish peroxidase, .beta.-lactamase, .beta.-galactosidase, and urease.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16054899P | 1999-10-20 | 1999-10-20 | |
US60/160,548 | 1999-10-20 | ||
PCT/US2000/041195 WO2001029090A1 (en) | 1999-10-20 | 2000-10-17 | Immunological assay for detection of antibodies in celiac disease |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2387359A1 true CA2387359A1 (en) | 2001-04-26 |
Family
ID=22577339
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002387359A Abandoned CA2387359A1 (en) | 1999-10-20 | 2000-10-17 | Immunological assay for detection of antibodies in celiac disease |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP1222210A4 (en) |
AU (1) | AU1966201A (en) |
CA (1) | CA2387359A1 (en) |
WO (1) | WO2001029090A1 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CU22968A1 (en) * | 2000-06-07 | 2004-07-14 | Ct Ingenieria Genetica Biotech | PROCEDURE FOR THE DETECTION OF ANTI-TRANSGLUTAMINASE ANTIBODIES USED IN THE DIAGNOSIS OF CELIAC DISEASE |
FR2857453B1 (en) * | 2003-07-11 | 2007-04-20 | Covalab | METHOD FOR THE SEROLOGICAL DETECTION OF CELIAC DISEASE AND ASSOCIATED DIAGNOSTIC NEEDS |
CA3009238C (en) * | 2011-01-20 | 2020-10-27 | Cyrex Laboratories, Llc | Methods and apparatus for detection of gluten sensitivity, and its differentiation from celiac disease |
CN108676863B (en) * | 2017-05-18 | 2022-05-03 | 四川出入境检验检疫局检验检疫技术中心 | Method for identifying celiac allergen in wheat flour by high-throughput sequencing technology |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE9001582D0 (en) * | 1990-05-03 | 1990-05-03 | Dagny Birgitta Hessel | SET FOR QUANTITATIVE DETERMINATION OF FIBRINOGEN, FIBRONECTIN, ALFA-2 ANTIPLASMIN OR FACTOR XIII |
DE4038899C2 (en) * | 1990-12-06 | 1995-01-19 | Dempfle Carl Erik Dr Med | Methods and reagents for the determination of the enzymatic activity of transglutaminases (EC 2.3.2.13) |
DE19630557C2 (en) * | 1996-07-18 | 1998-07-02 | Schuppan Detlef Priv Doz Dr Dr | Method for the detection of antibodies from body fluids by an immune reaction with tissue transglutaminase (tTG) as well as the use of tTG in diagnosis and therapy |
US5972615A (en) * | 1998-01-21 | 1999-10-26 | Urocor, Inc. | Biomarkers and targets for diagnosis, prognosis and management of prostate disease |
US6388056B1 (en) * | 1998-10-26 | 2002-05-14 | Paula Sundstrom | Inhibition of transglutaminase-mediated microbial interaction with a mammalian host |
-
2000
- 2000-10-17 WO PCT/US2000/041195 patent/WO2001029090A1/en not_active Application Discontinuation
- 2000-10-17 AU AU19662/01A patent/AU1966201A/en not_active Abandoned
- 2000-10-17 EP EP00982660A patent/EP1222210A4/en not_active Withdrawn
- 2000-10-17 CA CA002387359A patent/CA2387359A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
AU1966201A (en) | 2001-04-30 |
EP1222210A1 (en) | 2002-07-17 |
WO2001029090A1 (en) | 2001-04-26 |
EP1222210A4 (en) | 2004-12-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Bazzigaluppi et al. | Comparison of tissue transglutaminase-specific antibody assays with established antibody measurements for coeliac disease | |
US10481156B2 (en) | Detection of autoantibodies reactive with pancreatic islet cell antigenic molecules and/or insulin | |
JP4689597B2 (en) | Gastrin hormone immunoassay | |
JP3447010B2 (en) | Elimination of rheumatoid factor interference using anti-Fd antibody | |
CN113287013A (en) | Method for examining ulcerative colitis and primary sclerosing cholangitis | |
US20070184504A1 (en) | Assay for anti-INGAP antibodies | |
EP1164375B1 (en) | Assay for anti transglutaminase antibodies | |
US20130344474A1 (en) | Method and kit for detection of chronic hepatitis b | |
WO1998054218A1 (en) | Troponin i forms and use of same | |
US20080038760A1 (en) | Method for Detecting Anti-Transglutaminase Antibodies | |
US6703208B1 (en) | Immunological assay for detection of antibodies in celiac disease | |
CA2387359A1 (en) | Immunological assay for detection of antibodies in celiac disease | |
JP2000515854A (en) | Method for measuring the presence of brain protein S-100 | |
JP4274693B2 (en) | Crohn's disease test method and test kit | |
Nakachi et al. | Epitopes recognised by tissue transglutaminase antibodies in coeliac disease | |
US10156565B2 (en) | Peptide, magnetic peptide and method for detecting celiac disease | |
AU776091B2 (en) | Diagnosis of gluten sensitive enteropathy and other autoimmunopathies | |
JP2009294040A (en) | Examining method and examining reagent for autoimmune pancreatitis and fulminant type 1 diabetes mellitus | |
JP2003121444A5 (en) | ||
JP2004317502A (en) | Reagent for measuring anti-phosphatide antibody, and reagent kit | |
JP2010285416A (en) | Adm(amyopathic dermatomyositis) antibody epitope peptide and use of the same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Discontinued |